论文部分内容阅读
对426例急性白血病采用APAAP法23种单抗进行免疫分型研究.结果发现:(1)426例中,71.6%可确定为淋巴系或髓系或髓/淋混合型,28.4%不能确定细胞系列.FAB结果仅62.75%得到免疫表型证实,29.5%不能判断细胞起源,7.75%两者分型结果不一致;(2)ANLL140例中,44.29%免疫表型证实为髓细胞型,17.14%仅表达淋巴系标志,38.57%不能判断细胞起源,各髓系标志无明显FAB亚型特异性;(3)ALL260例中,72.67%进一步证实为淋巴细胞型,2. 69%单纯表达髓系标志或混合表达髓系和淋巴系抗原,另外24.62%不能确定细胞起源;(4)FAB不能分型26例中,23例可确定为ALL或ANLL,另外3例仍不能诊断.研究认为,免疫分型是FAB分型的必要补充.
For 426 cases of acute leukemia, 23 monoclonal antibodies to the APAAP method were used for immunophenotyping. The results showed that: (1) Of the 426 cases, 71.6% could be identified as lymphoid or myeloid or myelinated/lymphocytic, and 28.4% were unable to identify cells. Serial FAB results were only 62.75% confirmed by immunophenotype, 29.5% could not determine cell origin, and 7.75% were inconsistent in both types; (2) In 140 cases of ANLL, 44.29% of immunophenotypes were confirmed to be myeloid and 17.14% were only The expression of lymphoid markers, 38.57% can not determine the origin of cells, each myeloid lineage no obvious FAB subtype specificity; (3) Of the 260 cases of ALL, 72.67% were further confirmed as lymphocyte type, 2. 69% purely expressed myeloid markers or Mixed expression of myeloid and lymphoid antigens, another 24.62% can not determine the origin of the cell; (4) FAB can not be typed in 26 cases, 23 cases can be identified as ALL or ANLL, the other 3 cases still can not be diagnosed. Research believes that the immunophenotype Is a necessary supplement to the FAB classification.